1. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Issue 4 (April 2020) Authors: Fraser, Graeme L.; Lederman, Samuel; Waldbaum, Arthur; Kroll, Robin; Santoro, Nanette; Lee, Misun; Skillern, Laurence; Ramael, Steven Journal: Menopause Issue: Volume 27:Issue 4(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA). Issue 12 (December 2020) Authors: Santoro, Nanette; Waldbaum, Arthur; Lederman, Samuel; Kroll, Robin; Fraser, Graeme L.; Lademacher, Christopher; Skillern, Laurence; Young, James; Ramael, Steven Journal: Menopause Issue: Volume 27:Issue 12(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Phase 3 Study of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause [A132]. (May 2022) Authors: Lederman, Samuel; Shapiro CM, Marla; Stute, Petra; Lee, Misun; Wang, Xuegong; Neal-Perry, Genevieve Journal: Obstetrics and gynecology Issue: Volume 139(2022)Supplement 1 Page Start: 39S Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 12 (December 2022) Authors: Hardt, Karin; Vandebosch, An; Sadoff, Jerald; Le Gars, Mathieu; Truyers, Carla; Lowson, David; Van Dromme, Ilse; Vingerhoets, Johan; Kamphuis, Tobias; Scheper, Gert; Ruiz-Guiñazú, Javier; Faust, Saul N; Spinner, Christoph D; Schuitemaker, Hanneke; Van Hoof, Johan; Douoguih, Macaya; Struyf, Frank;... Journal: Lancet infectious diseases Issue: Volume 22:Issue 12(2022) Page Start: 1703 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. The neurokinin 3 receptor antagonist, fezolinetant, is effective in treatment of menopausal vasomotor symptoms: a randomized, placebo-controlled, double-blind, dose-ranging study. (June 2019) Authors: Fraser, Graeme; Lederman, Samuel; Waldbaum, Arthur; Lee, Misun; Skillern, Laurence; Ramael, Steven Journal: Maturitas Issue: Volume 124(2019) Page Start: 135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Issue 10382 (1st April 2023) Authors: Lederman, Samuel; Ottery, Faith D; Cano, Antonio; Santoro, Nanette; Shapiro, Marla; Stute, Petra; Thurston, Rebecca C; English, Marci; Franklin, Catherine; Lee, Misun; Neal-Perry, Genevieve Journal: Lancet Issue: Volume 401:Issue 10382(2023) Page Start: 1091 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial. Issue 4 (9th April 2023) Authors: Neal-Perry, Genevieve; Cano, Antonio; Lederman, Samuel; Nappi, Rossella E.; Santoro, Nanette; Wolfman, Wendy; English, Marci; Franklin, Catherine; Valluri, Udaya; Ottery, Faith D. Journal: Obstetrics and gynecology Issue: Volume 141:Issue 4(2023) Page Start: 737 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗